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ABSTRACT
Background Russia has one of the highest rates of
mortality from cardiovascular disease (CVD). At age
35–69 years, they are eight times higher than in
neighbouring Norway. Comparing profiles of blood-based
CVD biomarkers between these two populations can help
identify reasons for this substantial difference in risk.
Methods We compared age-standardised mean levels
of CVD biomarkers for men and women aged 40–69 years
measured in two cross-sectional population-based
studies: Know Your Heart (KYH) (Russia, 2015–2018;
n=4046) and the seventh wave of the Tromsø Study
(Tromsø 7) (Norway, 2015–2018; n=17 646).
A laboratory calibration study was performed to account
for inter-laboratory differences.
Results Levels of total, low-density lipoprotein-, high-
density lipoprotein-cholesterol and triglycerides were
comparable in KYH and Tromsø 7 studies. N-terminal pro-
b-type natriuretic peptide (NT-proBNP), high-sensitivity
cardiac troponin T (hs-cTnT) and high-sensitivity
C-reactive protein (hsCRP) were higher in KYH compared
with Tromsø 7 (NT-proBNP was higher by 54.1% (95% CI
41.5% to 67.8%) in men and by 30.8% (95% CI 22.9%
to 39.2%) in women; hs-cTnT—by 42.4% (95% CI
36.1% to 49.0%) in men and by 68.1% (95% CI 62.4%
to 73.9%) in women; hsCRP—by 33.3% (95% CI 26.1%
to 40.8%) in men and by 35.6% (95% CI 29.0% to
42.6%) in women). Exclusion of participants with pre-
existing coronary heart disease (279 men and 282
women) had no substantive effect.
Conclusions Differences in cholesterol fractions cannot
explain the difference in CVD mortality rate between
Russia and Norway. A non-ischemic pathway to the
cardiac damage reflected by raised NT-proBNP and hs-
cTnT is likely to contribute to high CVD mortality in Russia.
INTRODUCTION
Russia has one of the highest rates of mortality from
cardiovascular disease (CVD) in the world,1
although it has been falling since 2005.2 The causes
of this high CVDmortality are not fully understood.
Comparison of blood-based biomarkers and other
risk factors in Russia relative to other countries with
lower CVD risk should throw light on the likely
drivers of these differences in mortality. A small
number of such studies have been conducted with
blood-based biomarkers restricted to lipid profiles
(total cholesterol, low-density lipoprotein (LDL)-
cholesterol, high-density lipoprotein (HDL)-
cholesterol and triglycerides).3–6 These have gener-
ally found no major differences between Russia and
other countries.
Biomarkers such as high-sensitivity cardiac tropo-
nin T (hs-cTnT) and N-terminal pro-b-type
natriuretic peptide (NT-proBNP) provide informa-
tion on actual cardiovascular morbidity and are not
simply risk predictors. They have been increasingly
used in population-based research where they have
been shown to be independent predictors of CVD
events.7–9 Outside of acute ischaemic cardiac events,
hs-cTnT elevation is associated with future risk of
heart failure, which is supported by structural and
functional studies of the heart.10 NT-proBNP is used
in diagnostics of heart failure and is predictive of
heart failure in population-based cohorts,11 along
with atrial fibrillation and stroke.12 While some
controversy exists about the role of high-sensitivity
C-reactive protein (hsCRP) in CVDs,13 it is asso-
ciated with coronary heart disease, stroke and vas-
cular death independently of the traditional risk
factors.14 In fact, studies of large population-based
cohorts identified hsCRP, hs-cTnTand NT-proBNP
as the blood biomarkers that are the most predictive
of cardiovascular events.15
In this paper, data from the Know Your Heart
(KYH) study (Russia) and the Tromsø study
(Norway) are compared to establish the differences
in major cardiovascular biomarkers measured in
blood among men and women aged 40–69 years.
Norway has a CVD mortality rate approximately
eight times lower than that in Russia in this middle-
aged group16; thus, it provides a good contrast for
comparing CVD biomarker levels.
METHODS
Study populations
Know Your Heart (Russia). A random population-
based sample of participants aged 35–69 years
(n=5107) stratified by age, sex and district were
recruited in the cities of Arkhangelsk and
Novosibirsk (Russia).16 Trained interviewers
recruited and interviewed participants at home to
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ascertain information about their health, socio-demographic
characteristics and lifestyle (51% of approached agreed to parti-
cipate). Participants were then invited to take part in a health
check at an outpatient clinic and 4543 (89%) attended. Our
analysis is based on 4046 participants aged 40–69 years who
attended the health check and provided a blood sample. The
health check included blood pressure measurements, recording
of weight and height, a 12-lead ECG and biological sample
collection. The additional questionnaire collected data on health
problems, lifestyle and medication use. Within 2 hours after
venipuncture (non-fasting samples), blood was centrifuged,
serum was frozen (−80℃), and analysed in a single batch at the
end of the fieldwork in Moscow.16
TheTromsø Study (Norway). In Tromsø 7, all inhabitants of the
municipality of Tromsø aged 40 years and above were invited and
21 083 participated (65%). The subset of 17 646 participants
aged 40–69 years was included in our analysis. All participants
completed questionnaires and examinations including biological
sampling. The questionnaire covered lifestyle, medication use
and medical history. A random subsample (5965 participants)
attended a second visit. Blood samples (non-fasting) at both visits
were processed immediately after collection and the laboratory
assays of the biomarkers were performed the same day at the
Department of Laboratory Medicine, University Hospital of
Northern Norway (ISO certification NS-EN ISO 15 189:2012).
Study measurements
All participants in KYH and Tromsø 7 with blood sample collected
had measured lipid profile (total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides), a marker of systemic inflamma-
tion (hsCRP) and glycosylated haemoglobin (HbA1c)—
Supplementary Table S1. A marker of cardiac damage (hs-cTnT)
and a marker of cardiac wall stretch (NT-proBNP) were measured
in all KYH participants and in 1403 Tromsø 7 participants who
were either selected randomly (81%) to attend the second visit or
were invited because of their previous participation in the sixth
wave of the Tromsø study. The characteristics of those in Tromsø
study with measured cardiac biomarkers are very similar to that of
the total study sample (Supplementary Table S2).
Body mass index (BMI) was calculated as weight (kilo-
grams) divided by height (metres) squared. Mean systolic
and diastolic blood pressure was calculated as the mean
of second and third measurements. Waist circumference
(WC) was measured at the narrowest part of the trunk in
KYH, while in Tromsø 7, WC was measured at the umbilicus
level. To ensure WC was comparable between the two studies,
WC in Tromsø 7 was converted to the narrowest waist using
a conversion equation.17 Waist-to-hip ratio (WHR) was calcu-
lated by dividing WC by hip circumference. Smoking status
was categorised as current smokers, ex-smokers and never-
smokers. For current smokers, the number of cigarettes
smoked was specified as 1–10/day, 11–20/day and >20/day.
Education level was classified into three categories: primary/
secondary, upper secondary and tertiary. Diabetes was defined
as HbA1c concentration above 6.5%, or self-report of dia-
betes, or use of medication with ATC-code A10 (antidiabetics)
according to the Anatomical Therapeutic Chemical (ATC)
classification.18 Lipid-lowering drugs use was determined
according to recorded medications coded to the ATC classifi-
cation as C10 (lipid-modifying agents) or self-reported use.
The pre-existing coronary heart disease was determined as evi-
dence of previous myocardial infarction (MI) on ECG, self-report
of MI or grade 2 angina pectoris. ECGs from both studies were
coded according to the Minnesota code (MC 1.1–1.3)19 using the
same semi-automated system. Grade 2 angina was determined
using the Rose Angina Questionnaire (short version).20
Calibration of laboratory data
Differences in the laboratory procedures in KYH and Tromsø 7
bring the potential for systematic differences in biomarker mea-
surements between the two sites due to measurement error. This
was addressed by a recalibration study with split sample testing
(Supplementary Methods M1, Supplementary Tables S3–S5,
Supplementary Figures S1–S10). For that purpose, 100 serum
samples and 50 whole blood samples from KYH participants
were re-assayed in both the laboratories in Moscow and
Tromsø. The paired measurements were analysed using Deming
regression to derive the calibration equations.
Statistical analysis
Mean biomarker levels among men and women were compared
having age-standardised to the 2013 Standard European
Population. Biomarkers with skewed distributions (triglycerides,
hsCRP, hs-cTnT, NT-proBNP) were ln-transformed before ana-
lysis and geometrical means were presented. Multivariable linear
regression was used to assess if the differences in mean biomarker
levels in the two studies could be explained by differences in age
(Model1), smoking prevalence, BMI, WHR, blood pressure, dia-
betes, education level (in addition to age) (Model 2) and use of
lipid-lowering drugs (in addition to variables in Model 2)
(Model 3). For triglycerides, models were also adjusted for the
fasting status. The regression models for hs-cTnT and NT-
proBNP were repeated for study participants without previous
MI or grade 2 angina. For the regression modelling, data from
participants with complete information on all the covariates were
used. For skewed biomarkers, the regression coefficients were
back-transformed to be interpreted as a per cent difference
between studies. Based on finding evidence of an interaction
between age and study, the differences in biomarkers between
studies were presented separately for 40–54 and 55–69 year olds.
All analyses were done using recalibrated biomarkers
(Supplementary Table S5). To account for uncertainty in the esti-
mation of the calibration coefficients in the subsequent compara-
tive analysis, we used a ‘double-bootstrap’ approach, verified
using a simulation study (Supplementary Methods M2,
Supplementary Tables S6–S7), to obtain 95% CIs for the regres-
sion coefficients. Statistical analysis was performed usingR version
3.6.0 and SAS software 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Descriptive characteristics presented in table 1 show that men in
KYHwere on average older, had higher blood pressure and lower
BMI, and a higher proportion were current smokers, and had
diabetes, compared with men in Tromsø 7. Women in KYH were
on average older, had higher blood pressure and BMI, a higher
proportion had diabetes, and a lower proportion were current or
previous smokers, compared with women in Tromsø 7 (table 1).
The similar proportion of participants reported using lipid-
lowering drugs that could be identified by ATC code in KYH
and Tromsø 7; however, self-reported use of lipid-lowering drugs
was higher in KYH (table 1).
The age-standardised means of CVD biomarkers are compared
in table 2. The geometric means for hs-cTnT, NT-proBNP and
hsCRP were significantly higher in KYH compared with Tromsø
7 among both men and women. It is notable that KYH had
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a higher proportion of participants with detectable hs-cTnT:
98.6% compared with 64.4% in Tromsø 7.
Table 3 shows the conditional differences in mean biomarker
levels between the studies from three regression models. The age-
adjusted model shows that men and women in KYH had slightly
lower LDL- and HDL-cholesterol than in Tromsø 7, while trigly-
ceride levels in women were higher in KYH. Adjustment for
smoking, BMI, WHR, blood pressure, diabetes, education, and
use of lipid-lowering drugs use had little effect on these differ-
ences (Model 2 and Model 3).
In the age-adjusted model, hsCRP in KYHwas 33.3% (95%CI
26.1% to 40.8%) higher in men and 35.6% (95% CI 29.0% to
42.6%) higher in women compared with Tromsø 7 (untrans-
formed coefficients in table 3). The corresponding values for NT-
proBNPwere 54.1% (95%CI 41.5% to 67.8%) and 30.8% (95%
CI 22.9% to 39.2%), and for hs-cTnT—42.4% (95% CI 36.1%
to 49.0%) and 68.1% (95% CI 62.4% to 73.9%). There was
substantial attenuation of the differences in hsCRP due to adjust-
ment by smoking, BMI, WHR, blood pressure, diabetes and
education, but there remained evidence for differences between
the two studies (Model 2). For hs-cTnTand NT-proBNP, adjust-
ment did not change the estimate of the mean difference.
The differences in hs-cTnT and NT-proBNP remained when
the analysis was restricted to participants without previousMI, or
grade 2 angina (table 4).
The differences in biomarker levels between the two studies
differed by age group (table 5). For most biomarkers, study
differences were larger in women aged 55–69 years than
40–54 years. Among men, differences in hsCRP were more pro-
nounced in the older age group (55–69 years), while differences
in total and LDL-cholesterol were larger in younger men
(40–54 years).
Sensitivity analysis
As hs-cTnT assays are known to show appreciable imprecision at
the low values seen in the general population,21 we conducted
a sensitivity analysis using logistic regression with hs-cTnT cate-
gorised into values below and above the top quintile in this study
distribution (men—11 ng/L, women—8.07 ng/L). The results
were consistent with hs-cTnT analysed as a continuous outcome
(Supplementary Tables S8–S9). Adjustment for lipid-lowering
drugs based only on ATC codes in the regression model produced
similar results to the main analysis which defined lipid-lowering
drugs based on ATC code and self-reported use.
DISCUSSION
This comparison study shows that, after adjustment for sex and age,
the lipid profile was comparable in KYH (Russia) and in Tromsø 7
Table 1 Characteristics of the study sample (participants aged
40–69 years with blood sample collected): KYH (N=4046) and Tromsø
7 (N=17 555)
Men Women
KYH† Tromsø 7‡ KYH Tromsø 7
Age, mean (SD) 56.2 (8.5) 53.8 (8.5) 55.9 (8.7) 53.6 (8.4)
SBP, mean (SD) 138.6 (19.8) 130.8 (17.1) 129.9.0 (19.6) 123.4 (18.7)
DBP, mean (SD) 86.5 (11.3) 78.8 (9.7) 81.3 (11) 72.6 (9.6)
Hypertension§ 1102 (63.6) 3462 (41.5) 1337 (56.0) 2759 (29.7)
Smoking, N (%)
Current smoker >20/day 110 (6.5) 47 (0.6) 21 (0.9) 21 (0.2)
Current smoker 11–20/day 376 (22.2) 477 (5.8) 154 (6.6) 353 (3.9)
Current smoker 1–10/day 136 (8.0) 1083 (13.3) 200 (8.6) 1399 (15.3)
Ex-smoker 640 (37.8) 3329 (40.7) 370 (15.8) 4109 (44.8)
Never smoked 432 (25.5) 3226 (39.5) 1595 (68.1) 3279 (35.8)
BMI, mean (SD) 27.7 (4.8) 27.9 (4.0) 28.9 (6.2) 26.8 (4.9)
WHR, mean (SD) 0.95 (0.07) 0.94 (0.07) 0.85 (0.08) 0.79 (0.07)
HbA1c ≥6.5%, N (%) 195 (11.6) 404 (4.9) 262 (11.3) 264 (2.9)
Use of diabetes medication,
N (%)
76 (4.5) 350 (4.2) 170 (7.3) 271 (2.9)
Diabetes, N (%) 217 (12.8) 515 (6.2) 353 (15.1) 393 (4.3)
Lipid-lowering drugs (ATC code
C10 and/or self-report), N (%)
266 (15.7) 1090 (13.1) 468 (20.0) 837 (9.1)
Lipid-lowering drugs (ATC code
C10), N (%)
169 (10.8) 913 (10.9) 212 (9.9) 720 (7.74)
Education level
Primary/secondary 147 (8.7) 1624 (19.6) 134 (5.7) 1699 (18.36)
Upper secondary 878 (51.7) 2570 (31.0) 1280 (54.6) 2409 (26.0)
Tertiary 675 (39.7) 4108 (49.5) 932 (39.7) 5145 (55.6)
Pre-existing coronary heart
disease
238 (14.0) 471 (5.7) 259 (11.0) 215 (2.3)
†Missing data in KYH: SBP/DBP—334 (8.3%), smoking—12 (0.3%), BMI—12 (0.3%), WHR
—2 (0.1%), diabetes—18 (0.4%), HbA1c—51 (1.3%), diabetes medication—419 (10.4%).
‡Missing data in Tromsø 7: SBP/DBP—45 (0.3%), smoking—273 (1.6%), BMI—41 (0.2%),
WHR—65 (0.4%), HbA1c—135 (0.8%).
§Hypertension was defined as SBP >140 mmHg and/or DPB >90 mmHg and/or use of
antihypertensive medication (ATC codes C02 (antihypertensives), C03 (diuretics), C07 (beta-
blocking agents), C08 (calcium channel blockers), or C09 (agents operating on the renin-
angiotensin system) and/or self-reported use.
ATC, Anatomical Therapeutic Chemical; BMI, body mass index; DBP, diastolic blood pres-
sure; KYH, Know Your Heart; SBP, systolic blood pressure; WHR, waist-to-hip ratio.
Table 2 Age-standardised means† of CVD biomarkers in KYH and
Tromsø 7
KYH Tromsø 7
P value for
differenceN Mean (95% CI) N Mean (95% CI)
Men
Total cholesterol
(mmol/L)
1700 5.26 (5.21, 5.31) 8302 5.46 (5.44, 5.48) <0.001
HDL-cholesterol
(mmol/L)
1700 1.34 (1.32, 1.36) 8301 1.37 (1.36, 1.38) 0.002
LDL-cholesterol
(mmol/L)
1700 3.44 (3.39, 3.48) 8302 3.70 (3.67, 3.72) <0.001
Triglycerides
(mmol/L)‡
1700 1.45 (1.41, 1.49) 8302 1.54 (1.52, 1.55) <0.001
hsCRP (mg/L)‡ 1700 1.42 (1.35, 1.49) 8302 1.06 (1.04, 1.08) <0.001
NT-proBNP (pg/
ml)‡
1700 54.7 (52.4, 57.2) 650 35.3 (32.5, 38.4) <0.001
hs-cTnT (ng/L)‡ 1700 7.59 (7.42, 7.77) 645 5.23 (5.01, 5.46) <0.001
Women
Total cholesterol
(mmol/L)
2346 5.50 (5.46, 5.54) 9253 5.53 (5.51, 5.55) 0.138
HDL-cholesterol
(mmol/L)
2346 1.61 (1.59, 1.63) 9253 1.72 (1.71, 1.73) <0.001
LDL-cholesterol
(mmol/L)
2346 3.54 (3.50, 3.58) 9253 3.56 (3.54, 3.58) 0.569
Triglycerides
(mmol/L)‡
2346 1.30 (1.27, 1.32) 9253 1.18 (1.16, 1.19) <0.001
hsCRP (mg/L)‡ 2346 1.37 (1.32, 1.43) 9253 1.03 (1.01, 1.05) <0.001
NT-proBNP (pg/
mL)‡
2342 71.0 (68.9, 73.1) 762 56.5 (53.3, 59.8) <0.001
hs-cTnT (ng/L)‡ 2342 5.93 (5.83, 6.02) 758 3.58 (3.47, 3.69) <0.001
†Standardised to the Standard European Population 2013.
‡Geometric means are presented.
CVD, cardiovascular disease; HDL, high-density lipoprotein, hsCRP, high-sensitivity
C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; KYH, Know Your Heart;
LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-b-type natriuretic peptide.
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(Norway) despite the much higher cardiovascular mortality in
Russia. In contrast, biomarkers of cardiac damage have higher
concentrations in KYH than in Tromsø 7 even after excluding
participants with previous coronary artery disease. These results
are not explained by the higher prevalence of hypertension and
smoking in Russia, suggesting that mechanisms in addition to cor-
onary heart disease contribute to cardiovascular mortality in Russia.
Cholesterol fractions
All cholesterol fractions were slightly lower in KYH than in
Tromsø 7 among both men and women, although the magnitude
of this difference was small and would not translate into large
differences in risk of vascular events. This is notable given that
Russia has one of the highest CVD mortality rate and a large
proportion of CVD death in country’s mortality statistics are
attributed to coronary heart disease. These findings are consis-
tent with previous studies comparing lipid levels in Russia with
other countries, concluding that blood lipid profiles were similar
in Russia and Western countries.3–6,22–24
The differences in cholesterol measures between studies are
not explained by differences in prevalence of classic risk factors
and use of lipid-lowering drugs.
NT-proBNP
Levels of the cardiac wall stretch biomarker NT-proBNP were
higher in KYH compared with Tromsø 7 among both men and
women. The differences were not explained by classic CVD risk
factors (blood pressure, smoking, BMI, WHR, diabetes). Among
women, we found difference between studies only in the older
age group (55–69 years old).
Elevated NT-proBNP is a biomarker of cardiac dysfunction
related to several pathological processes in the cardiovascular
system: heart failure,25 atrial fibrillation26 and stroke.12 We
suggest that elevated NT-proBNP in KYH compared with
Tromsø 7 may be explained by higher heart damage due to
non-ischaemic pathways to heart disease. Although heart
damage and the development of chronic heart failure can be
facilitated by MI or stable coronary heart disease, our con-
clusions were robust after exclusion of participants with
a history of coronary heart disease.
High-sensitivity cardiac troponin T
Similar to NT-proBNP, we found higher mean levels of hs-
cTnT in KYH compared with Tromsø 7 among both men and
women. This was not explained by a different prevalence of
classic CVD risk factors (smoking, BMI, WHR, blood pres-
sure, diabetes), but among women, the difference was more
Table 3 Differences† in mean biomarker levels in KYH vs Tromsø 7 adjusted for CVD risk factors
N Model 1 (adjusted for age)
Model 2 (adjusted for age, smoking, BMI,
WHR, SBP, DBP, diabetes, education)
Model 3 (adjusted for age, smoking, BMI, WHR, SBP,
DBP, diabetes, education, lipid-lowering drugs)
Men
Total
cholesterol
9669 −0.22 (−0.29, −0.1) −0.31 (−0.39, −0.19) −0.30 (−0.38, −0.17)
HDL 9669 −0.05 (−0.07, −0.02) −0.05 (−0.07, −0.02) −0.05 (−0.07, −0.02)
LDL 9679 −0.26 (−0.34, −0.22) −0.32 (−0.41, −0.28) −0.31 (−0.39, −0.27)
Triglycerides‡§ 9454 0.03 (0.00, 0.07) 0.02 (−0.01, 0.06) 0.02 (−0.01, 0.06)
hsCRP‡ 9669 0.29 (0.23, 0.35) 0.16 (0.10, 0.22) 0.17 (0.11, 0.22)
NT-proBNP‡ 2192 0.44 (0.36, 0.53) 0.37 (0.27, 0.47) 0.37 (0.27, 0.46)
hs-cTnT‡ 2197 0.36 (0.31, 0.40) 0.37 (0.32, 0.42) 0.37 (0.32, 0.42)
Women
Total
cholesterol
11 189 −0.07 (−0.15, 0.04) −0.13 (−0.21, −0.01) −0.09 (−0.17, 0.03)
HDL 11 189 −0.13 (−0.16, −0.11) −0.02 (−0.04, 0.01) −0.02 (−0.04, 0.01)
LDL 11 189 −0.03 (−0.10, 0.01) −0.13 (−0.21, −0.09) −0.09 (−0.17, −0.05)
Triglycerides‡ 10 859 0.10 (0.07, 0.12) 0.03 (0.00, 0.06) 0.03 (0.00, 0.06)
hsCRP‡ 11 189 0.31 (0.26, 0.35) 0.04 (−0.01, 0.10) 0.05 (0, 0.11)
NT-proBNP‡ 2876 0.27 (0.21, 0.33) 0.33 (0.25, 0.39) 0.32 (0.24, 0.38)
hs-cTnT‡ 2880 0.52 (0.48, 0.55) 0.49 (0.45, 0.53) 0.49 (0.45, 0.53)
†Values in KYH minus those in Tromsø 7 and 95% CIs, all models based on cases without missing data on adjustment variables.
‡Analysis is based on ln-transformed values.
§The models for triglycerides were additionally adjusted for fasting time because of differences in mean fasting time in the two studies. Fasting time was recorded from participants' self-report.
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein, hsCRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac
troponin T; KYH, Know Your Heart; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-b-type natriuretic peptide; systolic blood pressure; WHR, waist-to-hip ratio.
Table 4 The difference in mean levels of NT-proBNP and hs-cTnT in
KYH compared with Tromsø 7, adjusted for age.
Without coronary
heart disease With coronary heart disease
N
Mean difference
(95% CI) N
Mean difference
(95% CI)
Men
NT-proBNP† 1913 0.42 (0.33, 0.51) 279 0.34 (−0.02, 0.68)
hs-cTnT† 1918 0.35 (0.30, 0.40) 279 0.35 (0.17, 0.52)
Women
NT-proBNP† 2594 0.24 (0.18, 0.30) 282 0.49 (0.13, 0.81)
hs-cTnT† 2598 0.52 (0.49, 0.55) 282 0.38 (0.12, 0.58)
Analysis is stratified by pre-existing coronary heart disease (ECG or self-reported MI, grade 2
angina).
†Analysis is based on ln-transformed values.
hs-cTnT, high-sensitivity cardiac troponin T; KYH, Know Your Heart; MI, myocardial infarc-
tion; NT-proBNP, N-terminal pro-b-type natriuretic peptide.
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pronounced in the older age group (55–69 years old). Our
study is the first to measure hs-cTnT in a general population
in Russia. Several studies in the US and Western Europe used
hs-cTnT measurements in population samples free of known
CVD to predict future CVD.15 27 High hs-cTnTwas recognised
as an indicator of heart failure rather than ischaemic damage.9
10 Biochemical evidence of myocyte injury was associated with
subsequent imaging evidence of replacement fibrosis both in the
sample of asymptomatic individuals9 and in symptomatic non-
ischaemic heart disease populations.28–30 Even in patients with
chronic coronary artery disease, hs-cTnT was associated with
death and heart failure but not MI.31 It is notable that exclusion
of participants with pre-existing coronary heart disease in our
study did not change the estimates of the differences in hs-cTnT
substantially, neither did adjustment for hypertension and
smoking.
High-sensitivity C-reactive protein
This marker of systemic inflammation was higher in KYH than in
Tromsø 7. The differences are of similar magnitude among men
and women, are more pronounced in older age among men and
are appreciably attenuated by adjustment for classical CVD risk
factors (smoking, BMI, WHR, blood pressure, diabetes). Several
previous studies have investigated predictors of increased hsCRP
levels in Russian populations but did not report mean levels or
systematically compare them with western studies.6 32
Raised levels of hsCRP have been found to be predictive of
future CVD events14 33 and were associated with coronary pla-
que burden34 and atherosclerosis35; however, the relationship is
not considered to be causal.13 Low-grade elevation of hsCRP is
non-specific andmay reflect exposure to pro-inflammatory influ-
ences including smoking, particulate air pollutants, aspects of
diet, medications, oral cavity health, obesity and metabolic
syndrome.35While elevated hsCRP levels in KYH indicate higher
general inflammatory status in the participants, this may reflect
both atherosclerosis and higher prevalence of CVD risk factors,
like obesity and smoking. Although this study does not permit
inferences about the prevalence of atherosclerosis, elevated
hsCRP may indicate greater risk of future CVD outcomes in the
Russian sample.
Strengths and limitations
We analysed biomarker levels in recently obtained population-
based samples of men and women within the same age range in
the two studies. Similar methodology was used for data and
sample collection. A key strength is that a calibration study was
done to ensure the comparability of the laboratory essays for
biomarkers. Furthermore, an innovatory approach to calculate
CIs of the regression coefficients obtained using calibrated mea-
sures was developed to ensure 95% coverage.
Because the study was conducted in three cities, and
response rates in KYH were not optimal, we should be cau-
tious to generalise the findings to the whole of Norway and
Russia. The age distribution of the populations of
Novosibirsk and Arkhangelsk was similar to the national
average in both cities.16 Tromsø and Novosibirsk have higher
proportion of population with higher education compared
with respective national averages.16 36 However, it should
be noted that the selected locations have CVD mortality
rates that are similar to the national averages.16
Considering the ongoing changes in cardiovascular mortality in
Russia, there are many other factors that may explain recent reduc-
tion, including improvements in treatment for acute CVD events.2
However, in this paper, we were focusing on circulating biomarkers
in the general population rather than particular high-risk groups.
CONCLUSIONS
By comparing the blood biomarker profiles in comparable
population-based studies conducted in Russia and Norway, the
latter a country with much lower CVD mortality rates, we
attempted to identify the distinguishing features of CVD epi-
demic in contemporary Russia that make it unique to the rest of
the world. We have found the evidence that non-ischaemic
pathways beyond lipid-related mechanisms may take
a significant share of CVD morbidity in Russia. The higher
levels of NT-proBNP and hs-cTnT in Russia may indicate that
this population is at higher risk of dilated cardiomyopathy,
heart failure, atrial fibrillation and cardioembolic stroke. Very
minor differences in lipid levels are not enough to explain the
much high mortality due to coronary heart events in Russia
compared with Norway. However, higher pro-inflammatory
status reflected by hsCRP and contribution of higher levels of
hypertension, BMI and WHR (among women); smoking
(among men); and diabetes are very likely to contribute to
explaining the high coronary heart disease mortality in Russia.
To further explore heart damage, more in-depth characterisa-
tion of heart structure and function with echocardiography and
carotid ultrasound is required. Exploration of alcohol use as
Table 5 Age-stratified differences† in mean biomarker levels in KYH compared with Tromsø 7 by sex, adjusted for age (within strata)
Men Women
40–54 years old 55–69 years old P value for interaction 40–54 years old 55–69 years old p-value for interaction
Total cholesterol −0.27 (−0.36, −0.19) −0.17 (−0.25, −0.09) 0.077 0.05 (−0.01, 0.12) −0.18 (−0.25, −0.12) <0.001
HDL cholesterol −0.01 (−0.04, 0.02) −0.08 (−0.11, −0.05) 0.002 −0.03 (−0.06, 0.00) −0.22 (−0.25, −0.19) <0.001
LDL cholesterol −0.33 (−0.41, −0.25) −0.20 (−0.27, −0.13) 0.02 0.01 (−0.06, 0.07) −0.06 (−0.12, 0.00) 0.157
Triglycerides‡§ −0.01 (−0.06, 0.04) 0.07 (0.02, 0.11) 0.012 0.12 (0.09, 0.16) 0.19 (0.15, 0.22) 0.016
hsCRP‡ 0.18 (0.10, 0.25) 0.38 (0.31, 0.45) <0.001 0.19 (0.13, 0.26) 0.41 (0.34, 0.47) <0.001
NT-proBNP 0.33 (0.19, 0.48) 0.49 (0.39, 0.59) 0.081 0.07 (−0.03, 0.17) 0.40 (0.32, 0.47) <0.001
hs-cTnT‡ 0.35 (0.27, 0.43) 0.36 (0.31, 0.42) 0.788 0.44 (0.38, 0.49) 0.57 (0.53, 0.61) <0.001
†Values in KYH minus those in Tromsø 7.
‡Analysis is based on ln-transformed values.
§The models for triglycerides were additionally adjusted for fasting time because of differences in mean fasting time in two studies.
HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; KYH, Know Your Heart; LDL, low-density lipoprotein; NT-proBNP, N-terminal
pro-b-type natriuretic peptide.
lakunchykova O, et al. J Epidemiol Community Health 2020;0:1–7. doi:10.1136/jech-2020-213885 5
Original research
 on N
ovem
ber 12, 2020 by guest. P
rotected by copyright.
http://jech.bm
j.com
/
J E
pidem
iol C
om
m
unity H
ealth: first published as 10.1136/jech-2020-213885 on 15 M
ay 2020. D
ow
nloaded from
 
a potential explanation of biomarker differences should be
a potential future research direction.37
The results of this study are important from a prevention
perspective. As we suggest a substantive proportion of CVD in
Russia occurring due to non-ischaemic pathways, additional
efforts are needed to detect and treat people with early structural
and functional changes in the heart.
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